Aprea Therapeutics (NASDAQ:APRE) Announces Earnings Results

Aprea Therapeutics (NASDAQ:APRE) issued its earnings results on Monday. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.05, Yahoo Finance reports. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative return on equity of 56.78%. The firm had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $0.10 million.

Aprea Therapeutics Stock Down 1.5 %

Shares of NASDAQ:APRE traded down $0.05 during midday trading on Wednesday, hitting $3.25. The stock had a trading volume of 203 shares, compared to its average volume of 19,806. The company’s 50-day moving average price is $3.95 and its 200-day moving average price is $5.26. The company has a market capitalization of $17.65 million, a P/E ratio of -0.98 and a beta of 1.04. Aprea Therapeutics has a fifty-two week low of $3.20 and a fifty-two week high of $8.85.

Analyst Ratings Changes

A number of research analysts recently commented on APRE shares. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Aprea Therapeutics in a research note on Tuesday. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a research report on Monday.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.